Damon Runyon News
View New Articles By
This year, thirteen Damon Runyon alumni were chosen as American Association for the Advancement of Science (AAAS) Fellows in honor of their invaluable contributions to science and technology.
News
New Discoveries
New Discoveries
To understand all the genetic alterations driving melanoma, Damon Runyon Clinical Investigator Eliezer Van Allen, MD, and his colleagues at Dana-Farber Cancer Institute have assembled the largest molecular dataset on this disease and used it to uncover new details that may help in diagnosis and treatment.
New Discoveries
Damon Runyon-Rachleff Innovator Elli Papaemmanuil, PhD, and colleagues at Memorial Sloan Kettering Cancer Center have uncovered new clues that may help answer a troubling question—why do some patients develop a secondary blood cancer after receiving radiation or chemotherapy treatment for their initial cancer diagnosis?
New Discoveries
Pancreatic cancer is particularly difficult to diagnose since people usually have no symptoms until the cancer reaches a more advanced stage or spreads to other organs. Though progress against this cancer has been slow, Damon Runyon researchers are making an impact through understanding the biology and developing novel treatments.
New Discoveries
Researchers have conducted the biggest study ever into the path that individual blood cells take to becoming leukemia. Former Damon Runyon-Sohn Fellow Robert L. Bowman, PhD, Former Fellow Aaron D. Viny, MD, and colleagues at the Memorial Sloan Kettering Cancer Center examined how a series of stepwise mutations in normal blood cells could trigger the transformation to cancer.
New Discoveries
Many cancer immunotherapies, drugs that activate a patient’s immune system, have emerged in recent years, but none are universally effective. To address this shortcoming, Clinical Investigator Anusha Kalbasi, MD, and colleagues at the University of California Los Angeles found a drug that activates the body's natural defenses by behaving like a virus and may uncloak certain stealthy melanoma tumors, so they can be better targeted by immunotherapy.
New Discoveries
Former Damon Runyon Innovator Guillem Pratx, PhD, and colleagues at Stanford University have devised a way to use a common imaging technology called positron emission tomography, or PET, to watch the movement of a single cell injected into a laboratory mouse in real time.
New Discoveries
In developing a treatment plan for a patient, doctors rely on genetic tests on biopsied tumors in bulk rather than individual cells, which fails to capture the full extent of cellular diversity within tumors. A more complete picture of what is happening in a lung cancer tumor could yield clues for effective therapies that may benefit patients.
New Discoveries
Seven Damon Runyon scientists are recipients of the National Institutes of Health's High-Risk, High-Reward Research awards that will fund highly innovative and unusually impactful biomedical research proposed by extraordinarily creative scientists.
New Discoveries
Lung cancer is often missed in its earlier stages and, as a result, is the leading cause of cancer deaths in the United States. To tackle this issue, Damon Runyon Fellow Aaron L. Moye, PhD, and colleagues have developed a platform to study early-stage lung cancer and to identify potential new treatments.
CONNECT
1.877.7CANCER
info@damonrunyon.org
One Exchange Plaza
55 Broadway, Suite 302
New York, NY 10006
